MOMasaya Okuda

Masaya Okuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaya Okuda has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroyasu Yokomise

    Department of General Thoracic, Breast and Endocrinological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan

    12 shared publications
  • Jun Nakano

    Department of General thoracic Surgery, Faculty of Medicine, Kagawa University, Kita-Gun, Kagawa 761-0793, Japan

    6 shared publications
  • Dage Liu

    Department of General thoracic Surgery, Faculty of Medicine, Kagawa University, Kita-Gun, Kagawa 761-0793, Japan

    5 shared publications
  • Cheng-Long Huang

    Kagawa University

    4 shared publications
  • Hiroyasu Yokomise

    Department of General Thoracic, Breast and Endocrinological Surgery, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

    4 shared publications
  • Natsumi Matsuura

    Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, Kita-Gun, Japan

    4 shared publications

Latest Publications

  • Open Access

    Phanerochaete sordida as a cause of pulmonary nodule in an immunocompromised patient: a case report

    by Naoki Watanabe, Kiyofumi Ohkusu, Masaya Okuda, Osamu Imataki, Tomoya Ishii, Kiyoshi Negayama, Akira Tadokoro, Nobuyuki Kita, Takehiro Takagi, Nobuhiro Kanaji, et al.

    Phanerochaete sordida is a species of wood rotting fungus, which can degrade lignin, cellulose and hemicellulose contained in wood and other hard-to-biodegrade organic substances. However, to date, there have been no other reports demonstrating that P. sordida can infect humans. A 66-year-old Japanese man presented for a mass increasing in size on his left thigh. He had been suffering from rheumatoid arthritis for 18 years and chronic obstructive pulmonary disease for 20 years, for which he was being treated with 5 mg/day prednisolone and 8 mg/week methotrexate. The mass resection was performed two months later, and was diagnosed as malignant fibrous histiocytosis. However, a computed tomography examination for tumor recurrence after surgery showed a newly emergent pulmonary nodule. We therefore decided to resect the nodule by thoracoscopic procedure. Histopathological examination of the excised specimen showed that the lesion was a granuloma, with necrotic tissue and clumping of Aspergillus-like hyphae. Therefore, the nodule was diagnosed as a fungal infection and tissue specimens were cultured microbiologically. However, fungal growth was not observed. We consequently performed genetic analysis using a broad-range polymerase chain reaction. The 28S rRNA sequence demonstrated 100% homology with P. sordida using the NCBI BLAST program against the GenBank DNA databases. Using broad-range polymerase chain reaction, we identified P. sordida as the causative agent of a pulmonary nodule. These findings indicate that P. sordida may be an additional opportunistic causative organism of pulmonary infection in immunocompromised patients.


  • Correlation among the biomarkers for oral anti-cancer agents in lung adenocarcinoma.

    by Nariyasu Nakashima, Shinya Ishikawa, Dage Liu, Yoshimasa Tokunaga, Yoshuke Kita, Kazuhito Nii, Natsumi Matsuura, Jun Nakano, Shintaro Tarumi, Masaya Okuda, et al.

    E20015 Background: Oral administration is an easy and convenient way outpatient administration. It is also considered to be superior in terms of medical economics. In recent years, the development of individualized treatment in non-small cell lung cancer is remarkable, also the usefulness of biomarkers has been well proven. Among the biomarkers of oral anti-cancer agents, thymindylate synthase (TS) expression is related to 5-FU-based anti-tumor agent, and EGFR to TKI-based anti-tumor agent, in addition to the effectiveness of the c-Met-overexpressing in lung cancer has been evolved and phase III clinical trial of oral c-Met inhibitors have been reported. In oral therapeutic agents in lung adenocarcinoma, TS expression, EGFR mutation and c-Met expression was examined and its clinical significance will be applied to the future individualized therapy. Methods: For the tumors from 71 patients with lung adenocarcinoma who underwent surgery in our department, the intratumoral expression of TS and c-Met were evaluated with immunohistochemical staining. The status of EGFR mutations was examined by direct sequence method using extracted DNA from tumors. Results: (1) In the group observed the effect of corresponding therapeutic agent, TS negative was 40 cases (56.3%), EGFR mutant 23 was cases (32.3%), c-Met strongly positive was 17 cases (23.9%). (2) TS, c-Met expression, EGFR mutations, were proved to be the independent predictor for correspounding anti-cancer drug, and there were no significant correlation among these three biomarkers was abserved. (3) TS-negative or EGFR mutant-type was 49/71 (69.0%). Also in the TS-positive and EGFR wild-type, c-Met strongly positive example 5 cases (5/22 cases, 22.7%) was observed. It was considered to be the target of administration, if c-Met inhibitors is commercialized in the future. (4) The possible cases of individualized chemotherapy with oral therapeutic agents was 54/71 cases (76.1%). Conclusions: Three biomarkers in lung adenocarcinoma (TS, EGFR, c-Met) is respectively independent, the possibility of individualized treatment with oral agents based on biomarker analysis has been suggested.

  • Verification of biomarkers in predicting drug sensitivity with in vitro 3D drug sensitivity test in non-small cell lung cancer.

    by Dage Liu, Nariyasu Nakashima, Yoshuke Kita, Yoshimasa Tokunaga, Kazuhito Nii, Natsumi Matsuura, Jun Nakano, Shintaro Tarumi, Masaya Okuda, Tetsuhiko Go, et al.

    11602 Background: Various molecules have been reported to participate in the sensitivity of chemotherapy and their expression in tumor was used as biomarkers in predicting the response to chemotherapy clinically. Biomarkers have been applied to anti-cancer agent selecting and show a promising usefulness for individualized treatment. However, the utility of biomarkers was usually inspected by the clinical survival rate or the rate of reduction in tumors, direct correlation to the anti-cancer drug sensitivity has not been well proved. Collagen gel droplet embedded culture-drug sensitivity test (CD-DST) is a newly developed in vitro chemosensitivity test that has several advantages over the conventional ones. The predictive value of biomarkers to the anti-cancer agent sensitivity was invested using CD-DST test in non-small cell lung cancer (NSCLC) tumor. Methods: Eighteen patients with primary NSCLC were recruited in this study. For CD-DST test, viable cells were collected from fresh surgical specimen and embed into the collagen gel droplets in 3D condition. Tumor cells were exposed to 5-FU or docetaxel (DOC) for 24 hours and further incubated with serum-free culture medium for 7 days. The in vitro sensitivity was expressed as the percentage T/C ratio, where T was the total volume of the treated group and C was the total volume of the control group. Expression of thymindylate synthase (TS) (biomarker for 5-FU) and beta III-tubulin (biomarker for DOC) was assessed by immunohistochemistry. Results: 1): Anti-cancer drug sensitivity: The sensitivity for 5F-U (T/C%) was 77.1 ± 18.1, and the sensitivity for DOC was 74.9 ± 22.8. 2): Expression of biomarkers: TS expression was 47.4 ± 32.8, and beta III tubulin expression was 42.2 ± 26.2. 3): Correlation: The expression of TS and beta III tubulin significantly correlated with drug sensitivity for 5-FU and DOC respectively (r = 0.635, p = 0.0046; r = 0.503, p = 0.0033). Higher expression of biomarkers indicated worse anti-cancer drug sensitivity. Conclusions: The significant correlation between the biomarkers and sensitivity to anti-cancer agent was proved in NSCLC tumors. CD-DST may become a useful tool in inspecting the usefulness of biomarkers.

    • 1 April 2015
      • Vol. 68  (4) , 262-5

    [Perioperative Management of Lung Cancer Patients with atrial fibrillation being treated by antiplatelet or anticoagulant therapy].

    by Shinya Ishikawa, Yoshitaka Kasai, Natsumi Matsuura, Shintaro Tarumi, Jun Nakano, Masaya Okuda, Masashi Goto, Dagu Ryu, Tetsuhiko Go, Hiroyasu Yokomise

    In an aging society, the high incidence of surgery for the patients with ischemic heart disease(IHD)or atrial fibrillation(Af) under antiplatelet or anticoagulant therapy is a great problem. Interruption of antiplatelet or anticoagulant oral agents in the perioperative period may increase the risk of coronary or cerebral events. We retrospectively reviewed the surgical outcomes for lung cancer patients with IHD or Af. We reviewed 135 patients with lung cancer(41~88 years;97 men) who had preoperative oral administration of antiplatelet or anticoagulant drugs for IHD or Af between 2005 and 2012 at 2 centers, and analyzed retrospectively the perioperative medications and complications. IHD, Af and vasospastic angina(VSA) were complicated in 94, 33 and 8 patients, respectively. Drugeluted and bare-metal stents had been placed in 18 and 19 patients. Oral agents were aspirin in 68 patients, ticlopidine in 10 patients, clopidogrel in 15 patients and warfarin in 25 patients. These agents were stopped 2 to 60 days before surgery. Perioperative heparinization was performed in 22 patients. Oral agents were restarted after confirmation of hemostasis and no need for further invasive treatment. The surgical procedures were lobectomy in 88 patients, segmentectomy in 19 and partial resection in 25. There were no hemorrhagic or thromboembolic complications in a perioperative period except 1 case of pulmonary hemorrhage and 1 case of cerebral infarction. No perioperative hospital death was documented. Short-term interruption of antiplatelet or anticoagulant drugs before lung cancer surgery and heparinization was acceptable from the view of perioperative outcomes.

  • A surgical case of pulmonary infection with Scedosporium apiospermum

    by Yoshimasa Tokunaga, Masaya Okuda, Toshihiro Ikeda, Kouichi Ito, Ayumu Kato, Hiroyasu Yokomise

    • 1 December 2013
      • Vol. 33  (12) , 5597-602

    Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.

    by Hiroyasu Yokomise, Dage Liu, Shinya Ishikawa, Tetsuhiko Go, Masashi Gotoh, Masaya Okuda, Shintaroh Tarumi, Yoshitaka Kasai, Natsumi Matsuura

    We have previously reported that low expression of excision repair cross-complementing-1 (ERCC1), class III β-tubulin (tubulin), thymidylate synthase (TYMS) and ribonucleotide reductase-M1 (RRM1) is indicative of a favorable prognosis in patients with c-N2,3 non-small cell lung cancer (NSCLC) treated with surgery after induction chemoradiotherapy. In the present study, we prospectively explored the tailor-made treatment menu for induction chemotherapy according to the status of biomarkers, and evaluated the biomarker status pre- and post-chemotherapy. Twenty-five patients with pathologically-proven NSCLC who were not appropriate candidates for initial surgery were enrolled (October 2010 to June 2012, stage IIIA/B/IV1a/1b;14/5/2/4 respectively). Immunohistochemistry was performed to evaluate intratumoral expression of biomarkers. Epidermal growth factor receptor (EGFR) mutation was evaluated by direct sequencing. Two to four cycles of chemotherapy were performed with or without concurrent radiation (50 Gy). Docetaxel (n=12), pemetrexed (n=4), S-1 (n=4), docetaxel-plus-bevacizumab (n=3), and pemetrexed-plus-bevacizumab (n=2), in combination with platinum were selected for the therapeutic regimen. Twenty-one (84.0%) patients exhibited good partial response, and underwent complete resection without major morbidity or mortality. Of these 21 patients, four achieved a pathologically-complete response (PCR), and 10 achieved a major pathological response. The 3-year overall survival rate was 58.7% for the 25 patients overall, and the 2-year overall survival rate was 73.6% for patients who underwent surgery. Among the 17 patients who underwent resection (except for four with PCR), the status of ERCC1, tubulin, TYMS, RRM1 and EGFR changed markedly after chemotherapy in six patients, eleven patients, eight patients, nine patients and one patient, respectively. Chemotherapy followed by surgery on the basis of biomarker examination is a challenging approach for patients with advanced NSCLC who otherwise have poor outcomes. Post-chemotherapy biomarker status changed markedly in many cases.


  • Open Access

    Innovative method using circulating tumor cells for prediction of the effects of induction therapy on locally advanced non-small cell lung cancer

    by Shintaro Tarumi, Masashi Gotoh, Yoshitaka Kasai, Natsumi Matsuura, Masaya Okuda, Tetsuhiko Go, Shinya Ishikawa, Hiroyasu Yokomise

    The existence of circulating tumor cells (CTCs) in patients with lung cancer has been reported. The purpose of this study was to assess whether CTCs are predictive of the pathological effects of induction chemoradiotherapy for patients with non-small cell lung cancer.


  • A case of intercostal lung hernia from previous thoracotomy space

    by Naoya Yokota, Kouichi Itou, Yoshimasa Tokunaga, Yoshitaka Kasai, Masaya Okuda, Hiroyasu Yokomise

    • 1 June 2010
      • Vol. 16  (3) , 194-7

    Progressive growth of primary synovial sarcoma of the lung.

    by Jun Nakano, Hiroyasu Yokomise, Cheng-Long Huang, Noriyuki Misaki, Sung-Soo Chang, Masaya Okuda, Yoshio Kushida, Reiji Haba

    An 80-year-old male was admitted because of a giant mass in the left lower lobe of the lung on a routine chest X-ray. Chest computed tomography verified this to be a well-defined heterogeneous mass as described with no associated lymphadenopathy. FDG-PET depicted moderately marginal FDG uptake. The patient underwent a left lower lobectomy and lymphadenectomy. Grossly, the tumor measured 60 × 50 mm and was uniformly filled with a pure white, pudding-like friable substance. No lymph node metastasis was observed microscopically. Histologically, the tumor showed a dense proliferation of rounded or spindled malignant cells with a frequent mitotic activity and an increased nuclear-to-cytoplasmic ratio. The immunohistochemical staining was positive for vimentin, negative for cytokeratin, keratin-wide, EMA, CD34. A SYT-SSX2 fusion gene transcript was detected as a result of RT-PCR analysis. Because of these results, the tumor was diagnosed as a monophasic synovial sarcoma.


    • 1 December 2009
      • Vol. 15  (6) , 401-3

    Solitary fibrous tumor of the pleura presenting dry cough induced by postural position.

    by Masaya Okuda, Hiroyasu Yokomise, Sung-Soo Chang, Jun Nakano, Noriyuki Misaki

    Solitary fibrous tumor of the pleura is one of the uncommon diseases. About 40% of solitary fibrous tumors of the pleura are of a visceral and peduncled type. Several visceral pleural tumors have motility. A proof of motility of the intrathoracic tumor is useful for preoperative diagnosis. We report a resected case of solitary fibrous tumor of the pleura presenting dry cough induced by postural position.